Shots:

• Lupus Therapeutics (subsidiary of Lupus Research Alliance) collaborates with Takeda to evaluate TAK-079 (NCT03724916) in P-I clinical study assessing TAK-079 vs PBO in 24 patients with moderate to severe systemic lupus erythematosus (SLE)
• The P-I study evaluates Takeda’s TAK-079 safety- efficacy- PK/PD and will conduct in 20 research centers including member of Lupus Therapeutics’ Lupus Clinical Investigators Network (LuCIN)
• TAK-079 (SC) is a mAb- targets CD38 protein- reduces the immune cell expressing CD38 protein responsible for producing autoantibodies

Ref: Takeda | Image: Takeda